A new review in Blood Cancer Discovery outlines a key regulatory decision by an FDA committee that greenlights a new biomarker endpoint for accelerated drug approval in multiple myeloma and could cut a decade off the drug development process.
A new review in Blood Cancer Discovery outlines a key regulatory decision by an FDA committee that greenlights a new biomarker endpoint for accelerated drug approval in multiple myeloma and could cut a decade off the drug development process.
Designed by doctors. Powered by AI.
Owned by you.